AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16871748 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 40 mg
Number of subjects: 76
Study 11858102 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis + withdrawal of long‐acting nitrate
Number of subjects: 85
Study 11858102 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of nitrates only
Number of subjects: 85
Study 9917431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) 6.0 micromol/kg birth weight, single dose, intramuscular
Number of subjects: 84
Study 9917431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SnMP)
Number of subjects: 84
Study 9917431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP)
Number of subjects: 84
Study 8014496 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating combination regimen of chronic ganciclovir-foscarnet therapy
Number of subjects: 29
Study 8014496 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent combination regimen of chronic ganciclovir-foscarnet therapy
Number of subjects: 29
Study 8014496 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (adjunctive therapy)
Number of subjects: 29
Study 8014496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ganciclovir-foscarnet)
Number of subjects: 29
Study 2689574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 gm intravenously at the time of clamping of the cord
Number of subjects: 646
Study 2689574 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan 2 gm intravenously at the time of clamping of the cord
Number of subjects: 646
Study 788002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium sulphate
Number of subjects: 15
Study 788002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29384322 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) with two green kiwifruit
Number of subjects: 33
Study 29384322 — intervention group
Group type: COMPARATOR
Intervention: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) alone
Number of subjects: 33
Study 29141692 — intervention group
Group type: EXPERIMENTAL
Intervention: HomeStyles intervention
Number of subjects: 489
Study 29141692 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey completers
Number of subjects: 489
Study 25430687 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (110% motor-threshold; rightDLPFC, 1000 stimuli at 1 Hz + leftDLPFC, 1000 stimuli at 10 Hz)
Number of subjects: 56
Study 25430687 — intervention group
Group type: EXPERIMENTAL
Intervention: theta-burst stimulation (80% motor-threshold; rightDLPFC, continuous TBS, 1200 stimuli + leftDLPFC, intermittent TBS, 1200 stimuli)
Number of subjects: 56
Study 25430687 — intervention group
Group type: COMPARATOR
Intervention: sham TMS (sham coil with the TBS protocol)
Number of subjects: 56
Study 23790989 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Group (n=199) using a loyalty card to collect points and earn rewards for PA
Number of subjects: 406
Study 23790989 — intervention group
Group type: COMPARATOR
Intervention: No Incentive Group (n=207) using a loyalty card for self-monitoring without incentives
Number of subjects: 406
Study 20973908 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeHand® robotic camera holder
Number of subjects: 50
Study 20973908 — intervention group
Group type: COMPARATOR
Intervention: Manual camera control by human assistant
Number of subjects: 50
Study 20973908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FreeHand® and manual control)
Number of subjects: 50
Study 18410350 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 0
Study 18410350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16213066 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication defective herpes simplex virus vaccine (gH deletion) administered at 0 and 8 weeks, or 0, 4, and 8 weeks, or 0, 2, 4, and 8 weeks.
Number of subjects: 74
Study 16213066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 16213066 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sample collection for asymptomatic viral shedding
Number of subjects: 74
Study 12958082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (acute administration)
Number of subjects: 21
Study 12958082 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 21
Study 10718203 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (125-225 mg loading dose for 2 weeks, followed by 50-90 mg maintenance dose for 4 weeks)
Number of subjects: 39
Study 10718203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10718203 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 39
Study 9172970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior intervention (1 to 6 sessions)
Number of subjects: 132
Study 9172970 — intervention group
Group type: COMPARATOR
Intervention: Usual medical‐social care (control group)
Number of subjects: 132
Study 8491328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayre spatula
Number of subjects: 0
Study 8491328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayre spatula plus endocervical cytobrush
Number of subjects: 0
Study 8491328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervexbrush
Number of subjects: 0
Study 2959925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 179
Study 2959925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 31974770 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Meaning-Centered Psychotherapy-Palliative Care (IMCP-PC)
Number of subjects: 51
Study 31974770 — intervention group
Group type: COMPARATOR
Intervention: Counselling-based psychotherapy
Number of subjects: 51
Study 29362276 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medicines management (IMM) intervention including medication reconciliation, review, counselling, medication list, and post-discharge calls.
Number of subjects: 500
Study 29362276 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medicines management (IMM) intervention
Number of subjects: 500
Study 29362276 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500
Study 27568215 — intervention group
Group type: EXPERIMENTAL
Intervention: Obiltoxaximab (16 mg/kg IV)
Number of subjects: 390
Study 27568215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 25904041 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐820836 2 mg once daily for 14 days
Number of subjects: 120
Study 25904041 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐820836 4 mg once daily for 14 days
Number of subjects: 120
Study 25904041 — intervention group
Group type: COMPARATOR
Intervention: Encapsulated moxifloxacin 400 mg
Number of subjects: 120
Study 25904041 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 120
Study 23645003 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 1603
Study 23645003 — intervention group
Group type: COMPARATOR
Intervention: Lumbar Fusion
Number of subjects: 1603
Study 21216314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stocking at least one vaccine recommended for adults
Number of subjects: 886
Study 21216314 — intervention group
Group type: EXPERIMENTAL
Intervention: Plans to stop stocking vaccines
Number of subjects: 886
Study 21216314 — intervention group
Group type: EXPERIMENTAL
Intervention: Plans to increase vaccine purchases
Number of subjects: 886
Study 21216314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stocking all adult vaccines
Number of subjects: 886
Study 19063837 — intervention group
Group type: EXPERIMENTAL
Intervention: Herba Saxifragae cream (HS), applied externally twice a day for 4 weeks
Number of subjects: 42
Study 19063837 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC), applied externally twice a day for 4 weeks
Number of subjects: 42
Study 19063837 — intervention group
Group type: COMPARATOR
Intervention: Comparison of total scores of symptom score reducing index (SSRI)
Number of subjects: 42
Study 16938063 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement (ME) group
Number of subjects: 285
Study 16938063 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 285
Study 14659852 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-radiation therapy (188Re-MAG3)
Number of subjects: 59
Study 14659852 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 10623957 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking shoes
Number of subjects: 35
Study 10623957 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot
Number of subjects: 35
Study 10623957 — intervention group
Group type: COMPARATOR
Intervention: Dress shoes
Number of subjects: 35
Study 9180166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) treatment
Number of subjects: 9
Study 8256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk product (200 ml daily for six weeks)
Number of subjects: 58
Study 8256309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chemically acidified milk, 200 ml daily for six weeks)
Number of subjects: 58
Study 3916041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vaginal suppository of Gemeprost
Number of subjects: 180
Study 3916041 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 180
Study 29455756 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living Taught at Home (HEALTH) intervention
Number of subjects: 0
Study 29455756 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27692413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion using EDO
Number of subjects: 50
Study 27692413 — intervention group
Group type: COMPARATOR
Intervention: Hyrax expander
Number of subjects: 50
Study 25456365 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week)
Number of subjects: 1410
Study 25456365 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg/day)
Number of subjects: 1410
Study 23200931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 10 μg/hour
Number of subjects: 0
Study 23200931 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 20 μg/hour
Number of subjects: 0
Study 23200931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20965447 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 301
Study 20965447 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive TMS
Number of subjects: 301
Study 20965447 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 301
Study 18329223 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracurricular 12-step meetings
Number of subjects: 733
Study 18329223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sober recreational events
Number of subjects: 733
Study 18329223 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational sessions
Number of subjects: 733
Study 18329223 — intervention group
Group type: COMPARATOR
Intervention: Residential program
Number of subjects: 733
Study 18329223 — intervention group
Group type: COMPARATOR
Intervention: Day-hospital program
Number of subjects: 733
Study 16154788 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 18
Study 16154788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12849674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 50 mg/h
Number of subjects: 292
Study 12849674 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan 100 mg/h
Number of subjects: 292
Study 12849674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 10566411 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-delivered multimedia health educational program (Student Bodies)
Number of subjects: 0
Study 8983555 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable skin tacks
Number of subjects: 20
Study 8983555 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel staples
Number of subjects: 20
Study 1832182 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms intradermally (ID) in months 0, 1, 6
Number of subjects: 95
Study 1832182 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms subcutaneously (sc) in months 0, 1, 6
Number of subjects: 95
Study 458200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐4 vaccine
Number of subjects: 476
Study 458200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐7 vaccine (three vaccines group)
Number of subjects: 476
Study 458200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐7 vaccine (two vaccines group)
Number of subjects: 476
Study 458200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (three vaccines group)
Number of subjects: 476
Study 458200 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (one vaccine group)
Number of subjects: 476
Study 458200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study 31976527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI (≥ 28 kg/m2, quartile 4)
Number of subjects: 10805
Study 31976527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased WC (≥ 91 cm for females, quartile 4)
Number of subjects: 10805
Study 31976527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased WC (≥ 79 cm for males, quartile 2-4)
Number of subjects: 10805
Study 31976527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BMI and increased WC (joint analysis)
Number of subjects: 10805
Study 31976527 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased WC only
Number of subjects: 10805
Study 30652262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (C + I group)
Number of subjects: 406
Study 30652262 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg (I group)
Number of subjects: 406
Study 28830251 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 53
Study 28830251 — intervention group
Group type: COMPARATOR
Intervention: Sham control (SHAM)
Number of subjects: 53
Study 25027772 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training (two 30-minute sessions per week for 7-8 weeks)
Number of subjects: 46
Study 25027772 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 46
Study 23011109 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations delivered in multiple directions (forward, backward, left, right, and combinations)
Number of subjects: 10
Study 23011109 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations delivered in multiple directions (left and right)
Number of subjects: 10
Study 23011109 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale assessment
Number of subjects: 10
Study 21426611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Approach (CBA) training for health visitors
Number of subjects: 0
Study 21426611 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centred Approach (PCA) training for health visitors
Number of subjects: 0
Study 19345067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 19345067 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 19345067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 19345067 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFalpha-antagonists
Number of subjects: 0
Study 16960171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract supplement drink (equivalent to 6 tomatoes)
Number of subjects: 23
Study 15561391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 36
Study 15561391 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 36
Study 11531665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in supine position
Number of subjects: 50
Study 11531665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in 15 degrees lateral tilt
Number of subjects: 50
Study 11531665 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure in supine position
Number of subjects: 50
Study 11531665 — intervention group
Group type: COMPARATOR
Intervention: No cricoid pressure in 15 degrees lateral tilt
Number of subjects: 50
Study 9248875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam as needed every 30 min for 4 h
Number of subjects: 37
Study 9248875 — intervention group
Group type: COMPARATOR
Intervention: 5 mg haloperidol as needed every 30 min for 4 h
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: G10‐3N dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: G120 M dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: CD 4000 dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: T 150 dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo‐Flux dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: F 60 dialyser
Number of subjects: 37
Study 8272247 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtral dialyser
Number of subjects: 37
Study 3828167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation
Number of subjects: 100
Study 3828167 — intervention group
Group type: COMPARATOR
Intervention: Oral intubation
Number of subjects: 100
Study 28951228 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir for 8 weeks
Number of subjects: 468
Study 28951228 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir for 12 weeks
Number of subjects: 468
Study 28951228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 468
Study 27888956 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized integrative nursing intervention
Number of subjects: 60
Study 27888956 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study 23743961 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (II) sulfate (Fe2+), 5 mg Fe/kg/d
Number of subjects: 65
Study 23743961 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (III)-hydroxide polymaltose complex (Fe3+)
Number of subjects: 65
Study 23743961 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study 23966142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 17
Study 23966142 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified incremental step test (MIST)
Number of subjects: 17
Study 23966142 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6-MWT)
Number of subjects: 17
Study 21227003 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 32
Study 21227003 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 32
Study 18418231 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteinemia (>16 micromol/l)
Number of subjects: 124
Study 18418231 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier acute coronary syndrome
Number of subjects: 124
Study 18418231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stroke
Number of subjects: 124
Study 18418231 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI
Number of subjects: 124
Study 16178704 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention program for couples
Number of subjects: 0
Study 16178704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention pilot study (Phase 2)
Number of subjects: 0
Study 12566473 — intervention group
Group type: EXPERIMENTAL
Intervention: +OC
Number of subjects: 30
Study 12566473 — intervention group
Group type: COMPARATOR
Intervention: -OC
Number of subjects: 30
Study 10573727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbutiamine 600 mg daily
Number of subjects: 326
Study 10573727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbutiamine 400 mg daily
Number of subjects: 326
Study 10573727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 9279680 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) PMMA intraocular lenses
Number of subjects: 99
Study 9279680 — intervention group
Group type: COMPARATOR
Intervention: Unmodified PMMA intraocular lenses
Number of subjects: 99
Study 1948264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (200 mg/day) combined with sulfamethoxazole (1000 mg/day)
Number of subjects: 383
Study 1948264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (200 mg/day) combined with sulfamethoxazole (1500 mg/day)
Number of subjects: 383
Study 1948264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil/sulfamethoxazole
Number of subjects: 383
Study 1948264 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine/dapsone (Maloprim)
Number of subjects: 383
Study 6341724 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated reminders
Number of subjects: 0
Study 6341724 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up without reminders
Number of subjects: 0
Study 31146022 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention offered to patients (n = 130)
Number of subjects: 260
Study 31146022 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 130)
Number of subjects: 260
Study 31146022 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 260
Study 31146022 — intervention group
Group type: EXPERIMENTAL
Intervention: TwiCs design
Number of subjects: 260
Study 27771617 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervising for Home Safety (SHS) program
Number of subjects: 95